W
William L. Holland
Researcher at University of Utah
Publications - 138
Citations - 11204
William L. Holland is an academic researcher from University of Utah. The author has contributed to research in topics: Insulin resistance & Ceramide. The author has an hindex of 44, co-authored 113 publications receiving 8890 citations. Previous affiliations of William L. Holland include University of Colorado Denver & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance
William L. Holland,Joseph T. Brozinick,Liping Wang,Eric D. Hawkins,Katherine M. Sargent,Yanqi Liu,Krishna K. Narra,Kyle L. Hoehn,Trina A. Knotts,Angela M. Siesky,Don H. Nelson,Sotirios K. Karathanasis,Greg K Fontenot,Morris J. Birnbaum,Scott A. Summers +14 more
TL;DR: It is demonstrated that the sphingolipid ceramide is a common molecular intermediate linking several different pathological metabolic stresses to the induction of insulin resistance, and enzymes required for ceramide synthesis are identified as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy.
Journal ArticleDOI
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
William L. Holland,Russell A. Miller,Zhao V. Wang,Kai Sun,Brian M. Barth,Hai H. Bui,Kathryn Davis,Benjamin T. Bikman,Nils Halberg,Nils Halberg,Joseph M. Rutkowski,Mark R. Wade,Vincent M. Tenorio,Ming Shang Kuo,Joseph T. Brozinick,Bei B. Zhang,Morris J. Birnbaum,Scott A. Summers,Scott A. Summers,Scott A. Summers,Philipp E. Scherer +20 more
TL;DR: Observations suggest a unifying mechanism of action for the beneficial systemic effects exerted by adiponectin, with sphingolipid metabolism as its core upstream signaling component.
Journal ArticleDOI
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich,Jenny Y. Chien,Haoda Fu,Leonard C. Glass,Mark A. Deeg,William L. Holland,Alexei Kharitonenkov,Bumol Thomas Frank,Holger K. Schilske,David E. Moller +9 more
TL;DR: Results indicate that FGF21 is bioactive in humans and suggest that F GF21-based therapies may be effective for the treatment of selected metabolic disorders, including obesity and type 2 diabetes.
Journal ArticleDOI
Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice.
William L. Holland,Benjamin T. Bikman,Liping Wang,Guan Yuguang,Katherine M. Sargent,Sarada Bulchand,Trina A. Knotts,Guanghou Shui,Deborah J. Clegg,Markus R. Wenk,Michael J. Pagliassotti,Philipp E. Scherer,Scott A. Summers,Scott A. Summers,Scott A. Summers +14 more
TL;DR: It is shown here that TLR4 is an upstream signaling component required for saturated fatty acid-induced ceramide biosynthesis, and that sphingolipids such as ceramide might be key components of the signaling networks that link lipid-induced inflammatory pathways to the antagonism of insulin action that contributes to diabetes.
Journal ArticleDOI
Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism
TL;DR: The role of ceramide and other sphingolipid metabolites in insulin resistance, beta-cell failure, cardiomyopathy, and vascular dysfunction is reviewed, focusing on in vivo studies that identify enzymes controlling sphingoipid metabolism as therapeutic targets for combating metabolic disease.